A Two-part Single- and Repeat-dose Study of CSJ137 in Anemic Chronic Hemodialysis Patients

Completed · Phase 1 · Has a placebo group

Conditions studied: Anemia, Iron-Deficiency

In brief

The study will assess the safety, tolerability and efficacy of CSJ137 in chronic hemodialysis patients. It is hypothesized that treatment with CSJ137 may improve the level of hemoglobin in patients on chronic hemodialysis with iron-restricted anemia while reducing the need for dosing with erythropoietin and intravenous iron in these patients.

Key facts

Study ID

NCT02570854

Run by

Novartis Pharmaceuticals

People needed

40

Starts

2015-09-22

Expected to finish

2020-05-13

Last updated by the study team

2021-10-12

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Hemodialysis-dependent for at least 2 months prior to screening.
• Receiving hemodialysis at least 2 times per week
• Receiving erythropoietin (EPO) therapy.
• Hemoglobin (Hgb) ≥ 8.5 and < 11.5 g/dL at screening.
• Ferritin >500 ng/mL and ≤ 2000 ng/mL at screening.
• TSAT ≤ 50% at a minimum of one time point during the 90 days prior to baseline.

You may not qualify if…

• Known diagnosis of hemochromatosis, bone marrow malignancy, lymphatic malignancy or myelodysplastic syndrome.
• History of dialysis AV fistula thrombosis within 2 months prior to screening, or 2 or more episodes of AV fistula thrombosis within 6 months prior to screening.
• Liver disease/dysfunction (Child-Pugh score ≥ 6), prior liver transplant, heart failure (NYHA Class III or IV); gastrointestinal bleeding.
• A positive Hepatitis B surface antigen test result. Patients with Hepatitis C Virus (HCV) infection may be included if all other liver function eligibility criteria are met.
• ALT, AST or bilirubin ≥ 1.5x ULN within 4 weeks prior to baseline.
• Uncontrolled renal osteodystrophy
• Conditions predisposing to an increased risk of serious infection, such as an indwelling vascular catheter (central venous line or non-tunneled/acute hemodialysis catheter) or active infection requiring antibiotic therapy at any time during the 2 weeks prior to screening. Tunneled hemodialysis catheters, and other "permanent" catheters are permitted.
• Blood transfusion administered within 4 weeks prior to baseline.
• Patients who received CSJ137 dose in the past.
• Other protocol-defined inclusion/exclusion criteria may apply.

Where it is running

• Novartis Investigative Site — San Diego, California, United States
• Novartis Investigative Site — Lakewood, Colorado, United States
• Novartis Investigative Site — Orlando, Florida, United States
• Novartis Investigative Site — Minneapolis, Minnesota, United States
• Novartis Investigative Site — Chattanooga, Tennessee, United States
• Novartis Investigative Site — Prague, Czechia
• Novartis Investigative Site — Ashkelon, Israel
• Novartis Investigative Site — Hadera, Israel
• Novartis Investigative Site — Jerusalem, Israel
• Novartis Investigative Site — Petah Tikva, Israel
• Novartis Investigative Site — Ramat Gan, Israel
• Novartis Investigative Site — Tel Aviv, Israel
• Novartis Investigative Site — London, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.